← Eichor
Study identifier: NCT03381625 Synced from ClinicalTrials.gov · July 28, 2026
● Completed

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Condition: Psoriasis · Atopic Dermatitis  ·  Sponsor: BioMimetix JV, LLC

PhasePhase 2
Planned participants139
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice daily for up to 28 days.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (10)

Encino Research CenterEncino, California, United States
Apex DermatologyDenver, Colorado, United States
Colorado Skin CareEnglewood, Colorado, United States
AboutSkin Dermatology & DermSurgeryGreenwood Village, Colorado, United States
Ciocca DermatologyMiami, Florida, United States
Dawes Fretzin Dermatology GroupIndianapolis, Indiana, United States
Juva Skin & Laser CenterNew York, New York, United States
Coastal Carolina Research CenterMt. Pleasant, South Carolina, United States
Dermatology Associates of NashvilleKnoxville, Tennessee, United States
Presicion Research InstituteHouston, Texas, United States

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03381625